Press Release : Roche receives positive CHMP -2-

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the twelfth consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2020 employed more than 100,000 people worldwide. In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 58.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

Blueprint Medicines, Gavreto and associated logos are trademarks of Blueprint Medicines Corporation.

References

[1] World Health Organization. Cancer [Internet; cited 2021 Sept]. Available from: https://www.globenewswire.com/Tracker?data=x1SQlQop7a9ZRhEkalD0G6PrjO8HlKwwgYiEYphMG5PI8MSf7x427BAaLaj3N3_CTcmJIGXFM_mp-69iilYL5kO6kXpzysQl7Y7UmzxM55Bfggi9w_xNT5Va39xJTH5-Ecn2UhKxivo-D0AuQHsorsEuYx7nc8TfBiDLi-85NEa8mBR0cRKNq_gmY-MQ7ktN https://www.who.int/news-room/fact-sheets/detail/cancer.

[2] American Cancer Society. Key Statistics for Lung Cancer [Internet; cited 2021 Sept]. Available from: https://www.globenewswire.com/Tracker?data=x1SQlQop7a9ZRhEkalD0G7ZWaTNk7psU-WGoGXoOjU2orMDp9cFD0_5AEyiGGIYIzWWbuxRPpfgVl9A5z46LnbhCfofz8q4gWWahemN_T6maJCg9S-i31jYlyZ10hjubTTjfYRV3xahJWTiAMzOtz08gzr9YqW3M9Hal0YCb36R8pLnYNMBx0LwUBC5IuZsp6ztzrEuIHZwpD45XzvuYGg== https://www.cancer.org/cancer/lung-cancer/about/key-statistics.html.

[3] Drilon A, et al. Brief Report: Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers. J Thorac Oncol. 2018;13:1595-601.

[4] Mazieres J, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019 Aug 1;30(8):1321-1328.

[5] Sabari J, et al. RET-rearranged lung cancers: Immunophenotype and response to immunotherapy. Journal of Clinical Oncology. 2018;36:9034-9034.

[6] Subbiah V, et al. Precision Targeted Therapy with BLU-667 for RET -Driven Cancers. Cancer Discov. 2018;8:836-849.

[7] Pakkala S, Ramalingam SS. Personalized therapy for lung cancer: striking a moving target. JCI Insight. 2018;3(15):e120858.

[8] Gainor J, et al. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. The Lancet. 2021;S1470-2045(21)00247-3.

[9] Subbiah V, et al. Clinical activity and safety of the RET inhibitor pralsetinib in patients with RET fusion-positive solid tumors: Update from the ARROW trial. Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2021; 04-08 Jun, 2021. Abstract #3079.

[10] ClinicalTrials.gov. Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (ARROW) [Internet; cited 2021 Sept]. Available from: https://www.globenewswire.com/Tracker?data=x1SQlQop7a9ZRhEkalD0G-PEQIoOIRyzmITzr0vNUMimrwPZHP_N1ygqR0VI2cqwnQYbH_h_vgNuCixeeUM011G_KRRemn3nJgzVf6HBaoRcS4ExYWC5Hsq3THu3inkSLNqe6MR4lv3SEYe1SoXaFY2tjqQ9Rf_yHPLS4mIE154= https://clinicaltrials.gov/ct2/show/NCT03037385.

[11] Curigliano G. Safety and efficacy of pralsetinib in patients with advanced RET fusion-positive non-small cell lung cancer: Update from the ARROW trial. Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2021; 04-08 Jun, 2021. Abstract #9089.

[12] Santoro M, et al. RET Gene Fusions in Malignancies of the Thyroid and Other Tissues. Genes. 2020;11(4):424.

[13] Romei C, et al. RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases. Oncotarget. 2018;9(11):9875-84.

Roche Group Media Relations

Phone: [phone] / e-mail: https://www.globenewswire.com/Tracker?data=qpSCSQiZ5I9zB3TMdwRmU2JDOMzLUiOEWHUhdm44QpDwJQEV-wCI8g032ribuiTOoTB9XwLc0xomyXJpgMiB-XWPy3xxUTz9kWsNuOwgsIw= media.re https://www.globenewswire.com/Tracker?data=dKm22DD6Kagl8Q9qNtzfv2rbcySpnmqeDaZtW1jBTR3Q_MuAVhuIRjggpH2gwWe5ARpLDBOfCOrE2Gifwmo6KU_scQaLw70NXL6YOW8201U= [e-mail]

 
Dr. Nicolas Dunant          Patrick Barth 
 Phone: [phone]     Phone: [phone] 
Nina Mählitz           Karsten Kleine 
 Phone: [phone]     Phone: [phone] 
Dr. Barbara von Schnurbein  Nathalie Meetz 
 Phone: [phone]     Phone: [phone] 
 
 
Roche Investor Relations 
Dr. Karl Mahler                               Jon Kaspar Bayard 
 Phone: [phone]                        Phone: [phone] 
 e-mail: mailto:[e-mail]          e-mail: mailto:[e-mail] 
 [e-mail]                         [e-mail] 
--------------------------------------------  ------------------------------------------- 
Dr. Sabine Borngräber                    Dr. Bruno Eschli 
 Phone: [phone]                        Phone: [phone] 
 e-mail: mailto:[e-mail]   e-mail: mailto:[e-mail] 
 [e-mail]                  [e-mail] 
--------------------------------------------  ------------------------------------------- 
Dr. Birgit Masjost                            Dr. Gerard Tobin 
 Phone: [phone]                        Phone: [phone] 
 e-mail: mailto:[e-mail]       e-mail: mailto:[e-mail] 
 [e-mail]                      [e-mail] 
--------------------------------------------  ------------------------------------------- 
 
Investor Relations North America 
Loren Kalm                                    Dr. Lisa Tuomi 
 Phone: [phone]                        Phone: [phone] 
 e-mail: mailto:[e-mail]            e-mail: mailto:[e-mail] 
 [e-mail]                           [e-mail] 
--------------------------------------------  ------------------------------------------- 
 

Attachment

   -- 17092021_MR_Gavreto CHMP 
      https://ml-eu.globenewswire.com/Resource/Download/1a6192f6-4fab-4a4b-8fa8-d3c5ba2a19c6

(END) Dow Jones Newswires

September 17, 2021 07:10 ET (11:10 GMT)